In summary, the present study demonstrates that PARP1, via activating PXR and promoting pro-toxic P450 enzymes, may represent a potential therapeutic target for the prevention and treatment of APAP-induced liver toxicity. This evidence concerns the gene CYP2B6 and hepatotoxicity.